MTHFR C677T polymorphism and risk of congenital heart defects: evidence from 29 case-control and TDT studies.

PloS one

PubMedID: 23536781

Wang W, Wang Y, Gong F, Zhu W, Fu S. MTHFR C677T polymorphism and risk of congenital heart defects: evidence from 29 case-control and TDT studies. PLoS ONE. 2013;8(3):e58041.
BACKGROUND
Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme for folate metabolism in humans; it is encoded by the MTHFR gene. Several studies have assessed the association between MTHFR C677T polymorphism and the risk of congenital heart defects (CHDs), while the results were inconsistent.

METHODS AND FINDINGS
Multiple electronic databases were searched to identify relevant studies published up to July 22, 2012. Data from case-control and TDT studies were integrated in an allelic model using the Catmap and Metafor software. Twenty-nine publications were included in this meta-analysis. The overall meta-analysis showed significant association between MTHFR C677T polymorphism and CHDs risk in children with heterogeneity (P heterogeneity?=?0.000) and publication bias (P egger?=?0.039), but it turned into null after the trim-and-fill method was implemented (OR?=?1.12, 95% CI?=?0.95-1.31). Nevertheless, positive results were obtained after stratified by ethnicity and sample size in all subgroups except the mixed population. For mothers, there was significant association between the variant and CHDs without heterogeneity (P heterogeneity?=?0.150, OR?=?1.16, 95% CI?=?1.05-1.29) and publication bias (P egger?=?0.981). However, the results varied across each subgroup in the stratified analysis of ethnicity and sample size.

CONCLUSIONS
Both infant and maternal MTHFR C677T polymorphisms may contribute to the risk of CHDs.